Dr Reddy's Laboratories Current Ratio 2010-2024 | RDY
Current and historical current ratio for Dr Reddy's Laboratories (RDY) from 2010 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Dr Reddy's Laboratories current ratio for the three months ending June 30, 2024 was 2.55.
Dr Reddy's Laboratories Current Ratio Historical Data |
Date |
Current Assets |
Current Liabilities |
Current Ratio |
2024-06-30 |
$3.23B |
$1.27B |
2.55 |
2024-03-31 |
$2.98B |
$1.15B |
2.58 |
2023-12-31 |
$2.87B |
$1.13B |
2.55 |
2023-09-30 |
$2.62B |
$1.01B |
2.59 |
2023-06-30 |
$2.56B |
$0.98B |
2.60 |
2023-03-31 |
$2.52B |
$1.04B |
2.41 |
2022-12-31 |
$2.35B |
$1.02B |
2.31 |
2022-09-30 |
$2.16B |
$0.98B |
2.19 |
2022-06-30 |
$2.27B |
$1.15B |
1.98 |
2022-03-31 |
$2.40B |
$1.24B |
1.94 |
2021-12-31 |
$2.24B |
$1.13B |
1.99 |
2021-09-30 |
$2.20B |
$1.16B |
1.90 |
2021-06-30 |
$2.14B |
$1.23B |
1.74 |
2021-03-31 |
$2.03B |
$1.14B |
1.78 |
2020-12-31 |
$1.83B |
$1.01B |
1.81 |
2020-09-30 |
$1.84B |
$1.07B |
1.72 |
2020-06-30 |
$1.76B |
$1.06B |
1.66 |
2020-03-31 |
$1.73B |
$0.97B |
1.79 |
2019-12-31 |
$1.64B |
$0.91B |
1.81 |
2019-09-30 |
$1.70B |
$0.87B |
1.96 |
2019-06-30 |
$1.68B |
$0.89B |
1.90 |
2019-03-31 |
$1.66B |
$0.86B |
1.92 |
2018-12-31 |
$1.62B |
$0.90B |
1.81 |
2018-09-30 |
$1.59B |
$0.98B |
1.62 |
2018-06-30 |
$1.68B |
$1.03B |
1.64 |
2018-03-31 |
$1.68B |
$1.07B |
1.57 |
2017-12-31 |
$1.72B |
$1.15B |
1.50 |
2017-09-30 |
$1.58B |
$1.08B |
1.46 |
2017-06-30 |
$1.55B |
$1.01B |
1.53 |
2017-03-31 |
$1.55B |
$1.31B |
1.18 |
2016-12-31 |
$1.55B |
$1.40B |
1.11 |
2016-09-30 |
$1.50B |
$1.34B |
1.12 |
2016-06-30 |
$1.51B |
$1.00B |
1.52 |
2016-03-31 |
$1.81B |
$0.98B |
1.85 |
2015-12-31 |
$1.80B |
$0.96B |
1.89 |
2015-09-30 |
$1.77B |
$1.00B |
1.77 |
2015-06-30 |
$1.82B |
$1.02B |
1.79 |
2015-03-31 |
$1.92B |
$1.03B |
1.87 |
2014-12-31 |
$1.77B |
$0.93B |
1.91 |
2014-09-30 |
$1.73B |
$0.88B |
1.96 |
2014-06-30 |
$1.76B |
$0.88B |
2.00 |
2014-03-31 |
$1.73B |
$0.90B |
1.92 |
2013-12-31 |
$1.65B |
$0.91B |
1.80 |
2013-09-30 |
$1.55B |
$0.88B |
1.77 |
2013-06-30 |
$1.54B |
$1.00B |
1.54 |
2013-03-31 |
$1.57B |
$0.98B |
1.60 |
2012-12-31 |
$1.54B |
$0.92B |
1.67 |
2012-09-30 |
$1.49B |
$0.90B |
1.66 |
2012-06-30 |
$1.34B |
$0.85B |
1.58 |
2012-03-31 |
$1.38B |
$0.85B |
1.61 |
2011-12-31 |
$1.36B |
$0.97B |
1.39 |
2011-09-30 |
$1.16B |
$1.05B |
1.10 |
2011-06-30 |
$1.09B |
$0.92B |
1.19 |
2011-03-31 |
$1.07B |
$0.92B |
1.16 |
2010-12-31 |
$0.92B |
$0.74B |
1.25 |
2010-09-30 |
$0.91B |
$0.71B |
1.28 |
2010-06-30 |
$0.92B |
$0.65B |
1.42 |
2010-03-31 |
$0.94B |
$0.65B |
1.45 |
2009-12-31 |
$0.80B |
$0.47B |
1.70 |
2009-09-30 |
$0.78B |
$0.50B |
1.57 |
2009-06-30 |
$0.82B |
$0.53B |
1.55 |
2009-03-31 |
$0.77B |
$0.52B |
1.47 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$12.399B |
$3.350B |
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
|